Stellara by J & J & # 039; is successful in a study of chronic intestinal disease

Stellara by J & J & # 039; is successful in a study of chronic intestinal disease https://www.eresviral.com/wp-content/uploads/2018/10/Stelara-de-J-amp-J-amp-039-tiene-éxito-en-un-estudio-de-enfermedad-intestinal-crónica

Stellara by J & J & # 039; is successful in a study of chronic intestinal disease







(Reuters) - Johnson & Johnson said on Tuesday that its successful drug Stelara was effective in treating chronic intestinal disease in an advanced-stage trial. 











FILE PHOTO: A Johnson & Johnson building is shown in Irvine, California, USA. UU., January 24, 2017. REUTERS / Mike Blake / Stock Photo





Two doses of Stelara, already approved for psoriasis, psoriatic arthritis and Crohn's disease, were tested in 961 patients with moderate to severe ulcerative colitis (UC) who had failed previous therapy. 

Doses of 6 mg / kg and 130 mg of intravenous therapy showed clinical remission in significantly more patients, compared with those who received placebo, after eight weeks, the company said. 

The treatment and placebo arms reported a similar proportion of side effects, and a patient with the 6 mg / kg dose died after excessive bleeding, J & J said. 

The patient had no history of high blood pressure or cirrhosis, said the drug manufacturer. 

"More than half of patients with UC have not experienced remission with the treatment options currently available," said the study's principal investigator, Bruce Sands. 

Stelara, which generated sales of $ 1,340 million in the second quarter of 2018, is also being tested in the lupus of autoimmune diseases. 

Ulcerative colitis, which affects approximately 38,000 people in the United States annually, is a chronic condition that causes abdominal pain, intestinal ulcers, bloody diarrhea, and weight loss. 

Current treatments include Xelijanz from Pfizer Inc., an oral treatment for adult patients with moderate to severe UC, and Renflexis from Merck & Co. 

(This story has been filled in to correct the dose to 130 mg, not 130 mg / kg in paragraph 3) 





Report of Manogna Maddipatla in Bengaluru; Edition by Sriraj Kalluvila





Our Rules:The principles of trust of Thomson Reuters.

        .
    .


SOURCE LINK ERESVIRAL.COM 
https://www.beviral.online